title: Tavaborole: first global approval.
abstract: Tavaborole is a novel, low-molecular weight oxaborole antifungal drug under development by Anacor Pharmaceuticals Inc. for the topical treatment of onychomycosis of the toenail. The drug has received its first global approval for this indication in the US. This article summarizes the milestones in the development of tavaborole leading to this first approval for onychomycosis of the toenails.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand, dru@adis.com.
authors.forename: Anthony
authors.initials: A
authors.lastname: Markham
mesh_terms: D000287:Administration, Topical; D000935:Antifungal Agents / Q000627:therapeutic use*; D001896:Boron Compounds / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D017277:Drug Approval; D015195:Drug Design; D005533:Foot Dermatoses / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C512998:tavaborole